Abstract Background Patients with Inflammatory Bowel Disease (IBD), i.e. Ulcerative colitis (UC) and Crohn’s Disease (CD), may suffer from genito-urinary tract-related disturbances. Whether lower urinary tract symptoms (LUTS) are more frequent in IBD patients is unclear. Objectives: 1) to assess the prevalence of LUTS in patients with IBD compared to controls (HC); 2) to define the role of clinical-demographic variables in this clinical setting. Methods Real-life, cross-sectional, multi-center study. LUTS were assessed in males and females through the International Prostatic Symptoms Score (IPSS) and the Bristol Female Lower Urinary Tract Symptoms (BFLUTS) questionnaires, respectively. IBD activity was assessed in CD by the CDAI, and in UC by PMS and TMS. Significance of differences was assessed by chi2 or Fisher’s exact test or Mann–Whitney or Kruskal–Wallis test, as appropriate. Correlation was tested by Spearman’s analysis. The level of statistical significance, corrected by the Bonferroni method for multiple testing, was set at p 0.017. Results 1) Two hundred forty-five IBD patients (35.5% CD, 64.5% UC), 152 males and 93 females, median age 47 yrs (34-61 yrs) and 142 HC 64 males and 78 females, median age 46 yrs (35-58 yrs) were included; 2) IPSS total score was higher in IBD patients than in HC 7 (3-12) vs 4 (1-8), respectively, p = 0.002, with no significant differences between CD and UC; 3) IPSS subscores of incomplete emptying and intermittency were significantly higher in IBD patients than in HC (p = 0.001 and p = 0.004, respectively); 4) A significantly higher percentage of IBD patients had moderate to severe IPSS total score compared to HC (28.5% vs 11.2%, p = 0.003); 5) BFLUTS total score, was higher in IBD patients, particularly in UC, than in HC 7 (3–12) vs. 4.5 (2–11.3), p = 0.044); 6) IBD activity showed a weak (i.e. r = 0.2-0.29) to moderate (r = 0.3-0.39) correlation with IPSS or BFLUTS. Conclusion 1) Prevalence of LUTS is higher in IBD patients than in controls with no differences between CD and UC; 2) IPSS moderate to severe total scores are more frequent in IBD patients than in controls; 3) Male IBD patients have significantly higher incomplete emptying and frequency IPSS subscores than controls; 4) IBD patients should be assessed for LUTS through validated questionnaires for prompt diagnosis and treatment. References: Romano L, Pellegrino R, Arcaniolo D, Gravina AG, Miranda A, Priadko K, De Gennaro N, Santonastaso A, Palladino G, Crocetto F, Barone B, Cuomo A, Facchiano A, Mucherino C, Spirito L, Sciorio C, de Sio M, Romano M, Napolitano L. Lower urinary tract symptoms in patients with inflammatory bowel diseases: A cross-sectional observational study. Dig Liver Dis. 2024 Apr;56(4):628-634. doi: 10.1016/j.dld.2023.10.010. Epub 2023 Oct 23. PMID: 37880017. Kim YN, Jung Y. [Renal and Urinary Manifestations of Inflammatory Bowel Disease. Korean J Gastroenterol. 2019 May 25;73(5):260-268. Korean. doi: 10.4166/kjg.2019.73.5.260. PMID: 31132832. Conflict of interest: Dr. Mucherino, Caterina: Takeda, Pfizer, Alfasigma, Galapagos, Johnson&Johnson, Palladino, Giovanna: Takeda Montesano, Laura: No conflict of interest D’Antonio, Elvira: No conflict of interest Romano, Marco: No conflict of interest Vespere, Giuliana: No conflict of interest Sedda, Silvia: No conflict of interest Piscitelli, Mario: No conflict of interest Luongo, Arianna: No conflict of interest Miranda, Agnese: No conflict of interest Cuomo, Antonio: Abbvie, Johnson & Johnson, Takeda, Lilly Sgambato, Dolores: No conflict of interest Capriolo, Anna: No conflict of interest Gravina, Antonietta Gerarda: Pfizer, Galapagos Biopharma, Abbvie Pellegrino, Raffaele: Pfizer Inc., Eli Lilly, Alfasigma, Abbvie
Mucherino et al. (Thu,) studied this question.